Human MMP-9 Antibody
R&D Systems, part of Bio-Techne | Catalog # MAB911
Key Product Details
Validated by
Knockout/Knockdown, Biological Validation
Species Reactivity
Validated:
Human
Cited:
Human
Applications
Validated:
CyTOF-reported, Immunohistochemistry, Immunoprecipitation, Western Blot
Cited:
Cell-based ELISA, Immunocytochemistry, Immunohistochemistry, Immunohistochemistry-Frozen, Immunohistochemistry-Paraffin, Immunoprecipitation, Luminex Development, Western Blot
Label
Unconjugated
Antibody Source
Monoclonal Mouse IgG1 Clone # 4H3
Product Specifications
Immunogen
Chinese hamster ovary cell line CHO-derived recombinant human MMP-9
Specificity
Detects human MMP-9 in Western blots. In Western blots, reactivity with the pro (92 kDa), active (82 kDa), and C-terminal truncated (65 kDa) forms of recombinant human (rh) MMP-9 is observed. Also in Western blots, 20% cross-reactivity with rhMMP-2, 5% cross‑reactivity with rhMMP-1, and no cross-reactivity with rhMMP-3, -7, -8, -10, -12, or -13 is observed.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1
Scientific Data Images for Human MMP-9 Antibody
Detection of Human MMP‑9 by Western Blot.
Western blot shows lysates of U937 human histiocytic lymphoma cell line untreated (-) or treated (+) with 5 ng/mL PMA for 24 hours. PVDF membrane was probed with 2 µg/mL of Mouse Anti-Human MMP-9 Monoclonal Antibody (Catalog # MAB911) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF018). A specific band was detected for MMP-9 at approximately 85 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.Detection of Canine MMP-9 by Western Blot
Effects of IGF-1 or/and PDGF-bb on IL-1 beta-induced NF-kappa B-dependent pro-inflammatory, pro-apoptotic and matrix degrading gene products in chondrocytes.To determine whether IGF-1 or/and PDGF-bbexert effects on IL-1 beta-induced NF-kappa B-dependent expression of pro-inflammatory, pro-apoptotic and matrix degrading gene products, primary chondrocytes were either stimulated with 10 ng/ml IL-1 beta, 10 ng/ml PDGF-bb, 10 ng/ml IGF-1 or combination of both growth factors (5 ng/ml each) or pre-stimulated for 12 h with 10 ng/ml PDGF-bb, 10 ng/ml IGF-1 or combination of both growth factors (5 ng/ml each) followed by 10 ng/ml IL-1 beta for 24. Equal amounts of total proteins were separated by SDS-PAGE and analyzed by immunoblotting using antibodies raised against COX-2, MMP-9 and MMP-13 and active caspase-3. Stimulation with IL-1 beta resulted in production of COX-2, MMP-9, MMP-13 and caspase-3 cleavage. Pre-treatment with a combination of both IGF-1 or/and PDGF-bb downregulated COX-2, MMP-9, MMP-13 and cleaved caspase-3. Image collected and cropped by CiteAb from the following publication (https://dx.plos.org/10.1371/journal.pone.0028663), licensed under a CC-BY license. Not internally tested by R&D Systems.Detection of Human MMP-9 by Knockdown Validated
MMP-9 positively regulates roundness and MLC2 activity(a) Cell morphology (roundness) of A375M2 cells on top of bovine collagen I after MMP-9 knockdown (siMMP-9). Dots represent single cells from two independent experiments. Representative F-actin-staining images are shown below. Scale bar, 20 μm. (b) Representative bright-field images of A375M2 cells on top of bovine collagen I after MMP-9 knockdown. Scale bar, 50 μm. (c) Representative immunoblot (top) and phospho-MLC2 (p-MLC2) levels (bottom) of A375M2 cells on bovine collagen I after MMP-9 knockdown. MMP-9 immunoblot is also shown (n = 9). (d) Representative confocal images (top) and quantification (bottom) of p-MLC2 immunostaining in A375M2 cells on bovine collagen I after MMP-9 knockdown. Dots represent single cells from three independent experiments. Scale bar, 25 μm. (e) Representative confocal images of A375P cells on bovine collagen I treated with 2 μg ml−1 recombinant purified proMMP-9 for 24 h. MMP-9 (cyan) and F-actin (red) stainings are shown. Scale bar, 25 μm. (f) Cell morphology (roundness) of A375P cells after proMMP-9 treatment for 24 h. Dots represent single cells from three independent experiments. (g) Representative proMMP-9 immunoblot in A375P cells on bovine collagen I after treatment with 2–4 μg ml−1 proMMP-9 for 24 h. (h) Diagram representing addition of A375M2- or A375P-secreted media to A375P cells on top of bovine collagen I. (i) Percentage of A375P elongated cells (associated with loss of cell rounding) grown on bovine collagen I for 24 h in the presence of secreted media from A375P, A375M2 or A375M2 siMMP-9 cells (n = 3). (j) Representative immunoblot (left) and p-MLC2 levels (right) in A375P cells on bovine collagen I for 24 h in the presence of secreted media from A375P, A375M2 or A375M2 siMMP-9 cells. MMP-9 immunoblot is also shown (n = 3). Graphs show mean±s.e.m. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. ANOVA with Tukey’s post hoc test (a,c,d,i,j), unpaired t-test (f). Image collected and cropped by CiteAb from the following publication (https://www.nature.com/articles/ncomms5255), licensed under a CC-BY license. Not internally tested by R&D Systems.Applications for Human MMP-9 Antibody
Application
Recommended Usage
CyTOF-reported
Brodie, T.M. et al. (2018) Cytometry Part
A. 93: 406. Ready to be labeled using established
conjugation methods. No BSA or other carrier proteins that could interfere with
conjugation.
Immunohistochemistry
25-100 µg/mL
Sample: Immersion fixed paraffin-embedded sections of human ovarian and breast cancer tissues
Sample: Immersion fixed paraffin-embedded sections of human ovarian and breast cancer tissues
Immunoprecipitation
25 µg/mL
Sample: Conditioned cell culture medium spiked with Recombinant Human MMP-9 (Catalog # 911-MP), see our available Western blot detection antibodies
Sample: Conditioned cell culture medium spiked with Recombinant Human MMP-9 (Catalog # 911-MP), see our available Western blot detection antibodies
Western Blot
2 µg/mL
Sample: U937 human histiocytic lymphoma cell line treated with PMA
Sample: U937 human histiocytic lymphoma cell line treated with PMA
Reviewed Applications
Read 1 review rated 4 using MAB911 in the following applications:
Formulation, Preparation, and Storage
Purification
Protein A or G purified from ascites
Reconstitution
Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: MMP-9
Long Name
Matrix Metalloproteinase 9
Alternate Names
CLG4B, Gelatinase B, GELB, MANDP2, MMP9
Gene Symbol
MMP9
Additional MMP-9 Products
Product Documents for Human MMP-9 Antibody
Product Specific Notices for Human MMP-9 Antibody
For research use only
Loading...
Loading...
Loading...
Loading...